Assessing the Benefit of Specialist Palliative Care in Oncology: Rethinking Clinical Trial Design
D
David Hui
M
Mellar P. Davis
(Department of Supportive Oncology, Levine Cancer Institute, Charlotte, NC)
J
Jennifer S. Temel
(Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital; Harvard Medical School, Boston, MA)
D
Dustin J. Rabideau
C
Camilla Zimmermann
Article Details
Journal
Journal of Clinical Oncology
Volume / Issue
Vol. 44, Issue 5
Published
February 10, 2026
Pages
349-355
ISSN
0732-183X
Publisher
Lippincott Williams & Wilkins
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences
Authors (5)
D
David Hui
M
Mellar P. Davis
Department of Supportive Oncology, Levine Cancer Institute, Charlotte, NC
J
Jennifer S. Temel
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital; Harvard Medical School, Boston, MA
D
Dustin J. Rabideau
C
Camilla Zimmermann
Related Articles from this Journal
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Ismaela Anna Vascotto, Filippo Antonica et al.
Aug 2026
10.1200/jco-26-00658
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Samer A. Srour, Jad Chahoud et al.
Aug 2026
10.1200/jco-26-00388
Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection
Risako Komata, Kenju Ando et al.
Aug 2026
10.1200/jco-26-00140
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Ghayas C. Issa, Branko Cuglievan et al.
Aug 2026
10.1200/jco-26-01743
Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Irbaz Bin Riaz, R. Bryan Rumble et al.
Aug 2026
10.1200/jco-26-01001